Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income/(Loss)	Accumulated Deficit	Total
Balance at the beginning of period at Dec. 31, 2019	$ 4	$ 364,712	$ 50	$ (165,863)	$ 198,903
Balance at the beginning of period (in shares) at Dec. 31, 2019	39,728,416
Increase (Decrease) in Stockholders' Equity
Exercise of stock options		370			370
Exercise of stock options (in shares)	25,778
Stock-based compensation expense		2,211			2,211
Stock-based compensation expense (in shares)	3,429
Foreign currency translation			25		25
Net income (loss)				(26,179)	(26,179)
Balance at the end of period at Mar. 31, 2020	$ 4	367,293	75	(192,042)	175,330
Balance at the end of period (in shares) at Mar. 31, 2020	39,757,623
Balance at the beginning of period at Dec. 31, 2019	$ 4	364,712	50	(165,863)	198,903
Balance at the beginning of period (in shares) at Dec. 31, 2019	39,728,416
Increase (Decrease) in Stockholders' Equity
Net income (loss)					(66,572)
Balance at the end of period at Jun. 30, 2020	$ 4	378,455	(16)	(232,435)	146,008
Balance at the end of period (in shares) at Jun. 30, 2020	40,014,519
Balance at the beginning of period at Mar. 31, 2020	$ 4	367,293	75	(192,042)	175,330
Balance at the beginning of period (in shares) at Mar. 31, 2020	39,757,623
Increase (Decrease) in Stockholders' Equity
Issuance of common stock		8,707			8,707
Issuance of common stock (in shares)	256,896
Stock-based compensation expense		2,455			2,455
Foreign currency translation			(91)		(91)
Net income (loss)				(40,393)	(40,393)
Balance at the end of period at Jun. 30, 2020	$ 4	378,455	(16)	(232,435)	146,008
Balance at the end of period (in shares) at Jun. 30, 2020	40,014,519
Balance at the beginning of period at Dec. 31, 2020	$ 4	391,558	(526)	(285,200)	105,836
Balance at the beginning of period (in shares) at Dec. 31, 2020	40,688,447
Increase (Decrease) in Stockholders' Equity
Issuance of common stock to investors, net of issuance costs		107,725			107,725
Issuance of common stock to investors, net of issuance costs (in shares)	2,804,878
Exercise of stock options		110			110
Exercise of stock options (in shares)	46,000
Stock-based compensation expense		4,698			4,698
Stock-based compensation expense (in shares)	9,094
Foreign currency translation			435		435
Net income (loss)				33,413	33,413
Balance at the end of period at Mar. 31, 2021	$ 4	504,091	(91)	(251,787)	252,217
Balance at the end of period (in shares) at Mar. 31, 2021	43,548,419
Balance at the beginning of period at Dec. 31, 2020	$ 4	391,558	(526)	(285,200)	$ 105,836
Balance at the beginning of period (in shares) at Dec. 31, 2020	40,688,447
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)					74,332
Net income (loss)					$ 10,476
Balance at the end of period at Jun. 30, 2021	$ 4	509,049	(13)	(274,724)	234,316
Balance at the end of period (in shares) at Jun. 30, 2021	43,576,950
Balance at the beginning of period at Mar. 31, 2021	$ 4	504,091	(91)	(251,787)	252,217
Balance at the beginning of period (in shares) at Mar. 31, 2021	43,548,419
Increase (Decrease) in Stockholders' Equity
Exercise of stock options		131			131
Exercise of stock options (in shares)	28,332
Stock-based compensation expense		4,827			4,827
Stock-based compensation expense (in shares)	199
Foreign currency translation			78		78
Net income (loss)				(22,937)	(22,937)
Balance at the end of period at Jun. 30, 2021	$ 4	$ 509,049	$ (13)	$ (274,724)	$ 234,316
Balance at the end of period (in shares) at Jun. 30, 2021	43,576,950